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Although plasmacytoid dendritic cells (pDCs) have been shown to
play a critical role in generating viral immunity and promoting
tolerance to suppress antitumor immunity, whether and how pDCs
cross-prime CD8 T cells in vivo remain controversial. Using a pDCtargeted vaccine model to deliver antigens specifically to pDCs, we
have demonstrated that pDC-targeted vaccination led to strong
cross-priming and durable CD8 T cell immunity. Surprisingly, crosspresenting pDCs required conventional DCs (cDCs) to achieve crosspriming in vivo by transferring antigens to cDCs. Taking advantage
of an in vitro system where only pDCs had access to antigens, we
further demonstrated that cross-presenting pDCs were unable to
efficiently prime CD8 T cells by themselves, but conferred antigennaive cDCs the capability of cross-priming CD8 T cells by transferring
antigens to cDCs. Although both cDC1s and cDC2s exhibited similar
efficiency in acquiring antigens from pDCs, cDC1s but not cDC2s
were required for cross-priming upon pDC-targeted vaccination,
suggesting that cDC1s played a critical role in pDC-mediated crosspriming independent of their function in antigen presentation. Antigen transfer from pDCs to cDCs was mediated by previously unreported pDC-derived exosomes (pDCexos), that were also
produced by pDCs under various conditions. Importantly, all these
pDCexos primed naive antigen-specific CD8 T cells only in the presence of bystander cDCs, similarly to cross-presenting pDCs, thus
identifying pDCexo-mediated antigen transfer to cDCs as a mechanism for pDCs to achieve cross-priming. In summary, our data suggest that pDCs employ a unique mechanism of pDCexo-mediated
antigen transfer to cDCs for cross-priming.
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in human cancers, indicating pDC-mediated anti-tumor immunity
(14, 18–22). However, how pDCs function in generating CD8
T cell immunity remains poorly understood.
Although initially thought of as the less efficient antigen presenting cells (APCs), pDCs can present antigens to activate both
CD4 T cells as well as CD8 T cells through cross-presentation
(23, 24). Cross-priming, the activation of naive CD8 T cells following DC-mediated cross-presentation—the process through
which exogenous antigens are processed and presented onto
MHC class I molecules—plays a major role in generating CD8
T cell immunity against cancers and viruses, upon vaccination, as
well as in the induction of immune tolerance (cross-tolerance)
(25–28). Recent discovery that type 1 cDCs (cDC1s) crossprimed antigen-specific CD8 T cells in tumors has highlighted
the importance of DC-mediated cross-priming in generating
CD8 T cell immunity and in determining the efficacy of cancer
immunotherapies, including immune checkpoint blockade (ICB)
(29–32). However, the function and roles of pDCs in crosspriming have remained understudied and not well understood.
In fact, despite pDCs having been shown to be capable of crosspresentation in vitro (33–37), even the involvement of pDCs in
cross-priming in vivo is still under debate (26, 38–40). Several
studies have suggested that pDCs were either not involved in or
Significance
Whether and how pDCs cross-prime CD8 T cells in vivo remain
controversial despite extensive studies. Using a vaccine model
where antigens were only delivered to pDCs, this report demonstrated that pDCs induced cross-priming and durable CD8
T cell immunity in vivo. However, cross-presenting pDCs required cDCs to achieve cross-priming by transferring antigens to
cDCs. cDC1s but not cDC2s played a critical role in pDC-mediated
cross-priming, despite both subsets acquiring antigens from
pDCs similarly. Antigen transfer from pDCs to bystander cDCs
was mediated by pDC-derived exosomes (pDCexos), which were
generated under various conditions. Importantly, these pDCexos
required cDCs to prime CD8 T cells, similarly to cross-presenting
pDCs, thus identifying the pDCexo/cDCs pathway as a mechanism for pDCs to achieve cross-priming.
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s the initiators of antigen-specific immune responses, dendritic cells (DCs) play a central role in regulating both T cell
immunity and tolerance (1). There are two major DC populations, conventional/classical DCs (cDCs) and the plasmacytoid DCs (pDCs). While both cDCs and pDCs could be
developed from a common DC progenitor (CDP) and share key
transcriptional factors and dependence on Fms-like tyrosine kinase 3 ligand (Flt3-L), pDCs were most noted as a unique DC
subset that produced large amount of type I interferons (IFN-I)
and have been extensively studied for their function in generating antiviral immunity by sensing viral RNA and DNA by tolllike receptor (TLR)-7 and -9 (2–10). Besides their function in
producing IFN-I, recent studies have also highlighted that pDCs
exert strong tolerogenic functions to mediate immune tolerance
by inducing T cell deletion, CD4 T cell anergy, and Treg differentiation (4, 11, 12). In tumors, pDCs are generally thought to
play a tolerogenic role, as accumulation of pDCs in multiple tumors was often associated with poor prognosis (4, 6, 13–17). On
the other hand, activation of pDCs has also been reported to induce immunogenic responses and has shown therapeutic efficacy
23730–23741 | PNAS | September 22, 2020 | vol. 117 | no. 38
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Results
Targeting pDCs In Vivo Led to Cross-Priming of Antigen-Specific CD8
T Cells. We have previously engineered recombinant anti-Siglec-H

and anti-Bst2 antibodies to express antigens of interest (anti-SiglecH-Ag and anti-Bst2-Ag) and shown that immunization with 10 to
20 μg of anti-Siglec-H-antigen specifically targeted pDCs but not
Fu et al.

cDCs in vivo, leading to presentation of antigens on MHCII for at
least 72 h (71, 72). As immunization with anti-Siglec-H-Ag have
been shown to prime CD4 T cell to mediate tolerance either with
or without adjuvant (71), we decided to first use pDC-targeting
anti-Siglec-H-OVA to examine whether pDCs cross-prime CD8
T cells in vivo, and if so whether pDC-mediated cross-priming
similarly leads to CD8 T cell tolerance. Wild-type (WT) mice
were immunized with anti-Siglec-H-OVA either with or without
TLR9 agonist CpG following adoptive transfer of 5- (6)-carboxyfluorescein diacetate succinimidyl diester (CFSE)-labeled OVAspecific CD8 T (OTI) cells, lymph node (LN) and spleen cells
were then examined for CD8 T cell responses. Immunization with
anti-Siglec-H-OVA alone led to some proliferation of OTI cells in
both LN and spleen (Fig. 1 A and B). However, the addition of
CpG greatly enhanced the proliferation of transferred OTI cells,
resulting in about a three- to fourfold increase in the percentages
of Thy1.1+ OTI cells in spleen and LN, respectively (Fig. 1A).
Examination of CFSE dilution further revealed that immunization
with anti-Siglec-H-OVA plus CpG resulted in about 80% of
Thy1.1 OTI T cells that have undergone more than five cycles of
proliferation, compared to 30 to 40% with anti-Siglec-H-OVA
alone (Fig. 1B). Thus, while the OVA antigen was cross-presented
to CD8 T cells by anti-Siglec-H-OVA alone, addition of an adjuvant CpG substantially improved efficacy of antigen crosspresentation.
To determine whether the proliferating OTI cells differentiated
into effector cells under these conditions, we examined IFN-γ
production. In LNs, while immunization with anti-Siglec-H-OVA
plus CpG resulted in about 50% IFN-γ-producing Thy1.1+ OTI
cells, immunization with anti-Siglec-H-OVA alone produced
much less IFN-γ-producing effector cells (<20%, Fig. 1C). Similar
results were obtained in spleen (Fig. 1C). Taken together, our data
suggested that anti-Siglec-H-OVA plus CpG were capable of efficiently priming naive OTI cells and induced their differentiation
into IFN-γ-producing effector cells.
As we previously have shown immunization with anti-Siglec-HOVA with or without the adjuvant led to CD4 T cell tolerance
(71), we asked whether our observed priming of naive CD8 T cells
(Fig. 1 A–C) similarly led to CD8 T cell tolerance. WT mice immunized with anti-Siglec-H-OVA alone or with CpG were recalled with OVA in Complete Freund’s Adjuvant (CFA) at 21 d. No
recall responses were observed in WT mice immunized with
anti-Siglec-H-OVA alone (Fig. 1D), suggesting that immunization
with anti-Siglec-H-OVA alone led to tolerance. However, strong
recall responses were observed in mice immunized with antiSiglec-H-OVA plus TLR9 agonist CpG as adjuvants (Fig. 1D),
suggesting that CD8 T cell tolerance was reversed, resulting in
CD8 T cell immunity when activation stimuli were provided, in
contrast to our data on CD4 T cell tolerance (71).
cDCs Are Required for Cross-Priming upon Immunization with AntiSiglec-H-OVA Plus CpG. We next asked whether pDCs alone were

sufficient for cross-priming. We generated CD11c-DTR→WT
bone marrow chimeras by transferring bone marrow cells of
CD11c-DTR (CD45.2) mice into lethally irradiated WT (CD45.1)
mice, which allow the depletion of cDCs but preserving the majority of pDCs (about 80%) upon treatment with diphtheria toxin
(DT) (73). Chimeras were treated with DT or phosphate buffered
saline (PBS), and immunized with anti-Siglec-H-OVA plus CpG
following adoptive transfer of CFSE-labeled naive OTI cells. While
chimeras treated with PBS exhibited strong cross-priming of naive
OTI cells with strong proliferation and differentiation into IFNγ-producing effectors, chimeras depleted of cDCs exhibited substantially reduced proliferation and percentages of IFN-γ-producing
effectors (Fig. 1 E and F), suggesting that cDCs might be required
for cross-priming by in vivo pDC-targeted vaccine with anti-Siglec-HOVA plus CpG. However, it should be noted that other non-DCs
might also contribute to pDC-mediated cross-priming based on
PNAS | September 22, 2020 | vol. 117 | no. 38 | 23731
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incapable of cross-priming in vivo. For example, pDCs did not
cross-present viral antigens during either influenza A virus (IAV)
or herpes simplex virus 1 (HSV-1) infection (41, 42), and depletion of pDCs did not affect cross-presentation and clearance
of viral antigens (43). CpG-stimulated pDCs have been shown to
be defective in cross-priming naive CD8 T cells compared to cDCs
(44), and pDCs were not able to cross-prime naive CD8 T cells
in vivo (45). On the other hand, other reports have suggested that
pDCs did cross-prime CD8 T cells in vivo (46–49). Despite the
controversy, however, it’s likely that pDCs at least play some roles
in regulating cross-priming, as increasing evidence has emerged
showing that both pDCs and cDCs are required to achieve optimal
cross-priming and CD8 T cell immunity under diverse conditions
(50–55). Furthermore, immunotherapies with pDCs either alone
or in combination with cDCs have shown promising clinical results
(18, 21, 22, 56, 57), although it remains unclear whether pDCs
exert their effects directly through their cross-priming or indirectly
by regulating other immune cells (i.e., cDCs, T cells, and natural
killer [NK] cells) through pDC activation and subsequent production of IFN-I and other cytokines (58, 59). Thus, there is a
critical need to better understand whether and how pDCs crossprime CD8 T cells to advance these promising pDC-based immunotherapies clinically.
Exosomes are small membrane vesicles about 30- to 150-nm
diameter in sizes that form within late multivesicular endosomal
compartments containing proteins, lipids, and nucleic acids, and
play an important role in intercellular communications and
material transfer of their cargo (60–63). DC-derived exosomes
(DCexos) additionally carry functional MHC class I/II-peptide
antigen complexes (pMHCI and pMHCII) and costimulatory
molecules and have been shown to prime both CD4 and CD8
T cells, making them attractive candidates as cancer vaccines
(64–67). Of note, whether pDCs generate exosomes and how
they function in priming CD8 T cells have not been investigated,
despite studies showing that pDC functions were regulated by
exosomes (68–70).
Here we report that delivering antigens specifically to pDCs by
targeting antibodies in vivo resulted in efficient cross-priming of
naive CD8 T cells and generation of durable immunity. However, efficient cross-priming of CD8 T cells in vivo required
cDCs that were not targeted, as depletion of cDCs abrogated
effector differentiation of CD8 T cells. Further analysis revealed
that while pDCs transferred antigens to cDCs leading to both
pDCs and cDCs expressing MHCI-antigen (pMHCI) complexes
on their surfaces, only cDCs but not pDCs effectively primed
naive OTI cells ex vivo. Taking advantage of an in vitro culture
system where antigens were only accessible to pDCs, we were
able to confirm the requirement of bystander cDCs for pDCmediated cross-priming, showing that cross-presenting pDCs
primed naive CD8 T cells by transferring antigens to bystander
cDCs. cDC1s but not cDC2s were required for pDC-mediated
cross-priming, despite both cDC1s and cDC2s receiving antigen
from pDCs similarly, suggesting that cDC1s played a critical role
in pDC-mediated cross-priming postantigen presentation. We
have further demonstrated that antigen transfer from pDCs to
bystander cDCs was mediated through pDC-derived exosomes
(pDCexos), which were also produced by pDCs under various
conditions. Importantly, these pDCexo primed naive antigenspecific CD8 T cells only in the presence of bystander cDCs, suggesting that a pDCexo-mediated cDC-dependent cross-priming
might be employed by pDCs to achieve cross-priming.

Fig. 1. Targeting pDCs by anti-Siglec-H-OVA plus CpG led to strong OVA-specific CD8 T cell responses that were dependent on cDCs. (A–C) WT mice were
immunized with anti-Siglec-H-OVA either alone or with CpG (n = 5), and cross-priming was examined as described in Materials and Methods. (A) The percentages of Thy1.1+ OTI cells out of total CD8 T cells are depicted with representative plots on the Left and bar graph with statistics analysis on the Right. The
percentages of Thy1.1+ OTI cells that had undergone more than five cycles of proliferation are depicted in B with representative histograms and bar graph
with statistics analysis. The percentages of IFN-γ+ cells out of total Thy1.1+ OTI cells are shown in C with representative plots and statistics analysis in bar graph.
Student’s t test was performed for A–F and NS = P > 0.05%, *P < 0.05, **P < 0.01, ***P < 0.001. (D) Immunization with pDC-targeting anti-Siglec-H-OVA alone
led to tolerance while immunization with anti-Siglec-H-OVA plus CpG led to strong recall responses. WT mice (n = 5) were immunized as in A and recalled at
21 d with OVA in CFA, and recall responses were examined. The percentages of Thy1.1+ OTI cells out of total CD8 T cells are depicted. (E and F) cDCs play a
critical role in cross-priming upon immunization with pDC-targeting anti-Siglec-H-OVA plus CpG. CD11c-DTR→WT bone marrow chimeras (n = 3 to 5) were
treated with DT or PBS on days −2, 0, and 2, and cross-priming was examined. The percentages of Thy1.1+ OTI cells out of total CD8 T cells are shown in E; and
mean and SD of the percentages of IFN-γ+ cells out of total Thy1.1+ OTI cells are shown in F. Data shown are representative of at least three independent
experiments.
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these data, as some macrophages and NK cells have been shown to
be depleted with the DT/CD11c-DTR system (73).
pDCs Targeted by Anti-Siglec-H-OVA Transfer Antigens to cDCs to
Prime Antigen-Specific CD8 T Cells. We next asked what the roles

pDCs and cDCs played in anti-Siglec-H-OVA-induced crosspriming in vivo. We first examined the expression of MHCIOVA complexes on DCs upon immunization. WT mice were
immunized with anti-Siglec-H-OVA plus CpG, and the expression of MHCI-OVA (H-2Kb-SIINFEKL) complexes on pDCs
23732 | www.pnas.org/cgi/doi/10.1073/pnas.2002345117

and cDCs was examined at various times after immunization,
taking advantage of the anti-H-2Kb-SIINFEKL antibody that
specifically recognizes the SIINFEKL epitope from OVA presented on MHCI (H-2Kb). MHCI-OVA complexes appeared on
pDCs in the spleen as early as 1 d after immunization and persisted for at least 4 d (Fig. 2 A and B, Upper). Interestingly,
significant expression of MHCI-OVA complexes was detected in
nontargeted cDCs with a slightly delayed kinetics (Fig. 2 A and
B, Lower). We also observed a similar pattern of MHCI-OVA
expression in LN pDCs and cDCs, with the exception that
Fu et al.
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cocultured with OTI in the presence or absence of naive cDCs that
had no contact with anti-Siglec-H-OVA throughout the experiments. While pDCs pulsed with anti-Siglec-H-OVA plus CpG efficiently presented OVA antigen on MHCI as detected by flow
cytometry (SI Appendix, Fig. S1), these pDCs are not efficient in
inducing proliferation of naive OTI cells (Fig. 3 A and B, Lower),
consistent with our ex vivo data on pDCs (Fig. 2D). Not surprisingly,
no proliferation was observed when OTI cells were cultured with
naive cDCs alone (Fig. 3A). However, when pDCs were added to
cDCs/OTI cocultures, strong proliferation of OTI cells was observed in a dose-dependent manner (Fig. 3 A, Upper). Importantly,
significant percentages of the proliferating OTI cells also differentiated into IFN-γ-producing effectors (Fig. 3 B, Upper), suggesting
that while cross-presenting pDCs alone were not sufficient to prime
naive antigen-specific CD8 T cells, the cooperation of crosspresenting pDCs and antigen-naive cDCs efficiently primed OTI
cells to become IFN-γ-producing effectors.
These results prompted us to test whether cross-presenting
pDCs (SI Appendix, Fig. S1) transfer antigen to naive cDCs, as
our in vivo data have suggested. Freshly isolated cDCs (CD45.1
or CD45.2) were cultured either alone or with cross-presenting
pDCs (different from cDCs for CD45). As shown in Fig. 3C,
coculture of naive cDCs with pulsed pDCs led to significant
expression of MHCI-OVA (H-2Kb-SIINFEKL) on cDCs. Thus,
our in vitro data have confirmed that cross-presenting pDCs
transferred antigens to antigen-naive cDCs and required cDCs to
prime naive antigen-specific CD8 T cells.
Batf3-Dependent cDC1s Played a Critical Role in Mediating pDCInduced Cross-Priming. Next we asked which cDC subsets are in-

volved in pDC-mediated cross-priming. As cDC1s have been shown
to play a critical role in initiating CD8 T cell immune responses
through cross-presentation in vivo (75), we asked whether cDC1s
played a critical role in mediating pDCs’ function in cross-priming.
We thus used Batf3−/− mice, which lack both CD8+ cDC1s and
migratory CD103+ cDC1s (75), to determine whether the loss of
cDC1s would affect cross-priming upon pDC-targeted vaccination
with anti-Siglec-H-OVA plus CpG. Significantly reduced percentages of the Thy1.1+ OTI cells in total CD8 T cells were observed in
Batf3−/− mice compared to WT mice (Fig. 4A), with the OTI cells
undergoing fewer rounds of proliferation (Fig. 4B). More strikingly,
the percentages of IFN-γ-producing effectors in both spleen and LN
of Batf3−/− mice were greatly reduced compared to WT mice
(Fig. 4C), suggesting that BATF3-dependent cDC1s (CD8+ and

Fig. 2. Targeting pDCs with anti-Siglec-H-OVA plus
CpG in vivo led to the expression of functional MHCIOVA (H-2Kb-SIINFEKL) complexes on cDCs. (A–C) WT
mice were immunized with anti-Siglec-H-OVA plus
CpG, and spleen and LNs were processed at indicated
times (n = 3) and subjected to flow cytometry. pDCs
and cDCs were gated as CD11cintermediate Bst2+ and
CD11chigh Bst2− cells, respectively. The percentages
of H-2Kb-SIINFEKL+ cells out of total pDCs and cDCs
in spleens are shown in A with representative flow
plots in B. The percentages of H-2Kb-SIINFEKL+ cells
out of total pDCs and cDCs in LNs are depicted in C.
Each time point was compared to controls. (D) cDCs
but not pDCs from immunized WT mice were able to
prime naive OTI CD8 T cells. pDCs and cDCs were
isolated from pooled spleens of WT mice immunized
as in A and then cocultured with naive OTI cells. The
percentages of IFN-γ+ cells out of total Thy1.1+ OTI
cells are shown (Upper), and the percentages of
proliferated (CFSElow) OTI cells out of total OTI cells
are shown (Lower). Data shown are representative
of three or more independent experiments. *P <
0.05, **P < 0.01, and ***P < 0.001.

Fu et al.
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significantly higher MHCI-OVA expression was detected on
cDCs on day 1 (Fig. 2C). As our previous study has shown that
anti-Siglec-H-Ag specifically delivered antigens to pDCs but not
cDCs in vivo (71), OVA antigens observed on nontargeted cDCs
in vivo were likely transferred from pDCs instead of mistargeting. Taken together, these data suggest that pDCs targeted by
anti-Siglec-H-OVA likely transfer OVA antigens to nontargeted
cDCs, leading to both pDCs and cDCs expressing MHCI-OVA
complexes on their surface.
As cDCs have been shown to be required for anti-SiglecH-OVA-induced cross-priming of naive antigen-specific CD8
T cells (Fig. 1 E and F), the findings that both pDCs and cDCs
presented OVA antigen on MHCI prompted us to examine the
contribution of pDCs and cDCs to CD8 T cell priming. WT mice
were immunized with anti-Siglec-H-OVA plus CpG, and cDCs
and pDCs were isolated from spleens at days 1 and 2 and
cocultured with naive OTI cells. Surprisingly, isolated pDCs did
not support OTI proliferation (Fig. 2D), despite their high expression of MHCI-OVA (Fig. 2A). Thus, although pDCs could
efficiently process and present OVA antigen onto MHCI to form
MHCI-OVA complexes on their surface, pDCs alone were not
sufficient to prime naive CD8 T cells. On the other hand, cDCs
depleted of pDCs by combining Pan DC isolation kit with a
mixture of antibodies against pDC-specific receptors (anti-B220,
anti-Siglec-H, and anti-Bst2; see Materials and Methods for details) were able to induce OTI proliferation as well as differentiation into IFN-γ-producing effectors (Fig. 2D). Taken together,
our data suggested that while pDCs targeted by anti-Siglec-HOVA in vivo efficiently presented antigens onto MHCI (as detected by anti-H-2Kb-SIINFEKL), cDCs that received antigen
from pDCs played a critical role in mediating cross-priming of
naive antigen-specific CD8 T cells.
Although our in vivo and ex vivo data strongly suggested that
pDCs transferred antigens to cDCs which then primed antigenspecific CD8 T cells, we could not rule out the involvement of
other cells/factors due to the complexity of the in vivo system. To
further confirm that cross-presenting pDCs transfer antigens to
cDCs to mediate cross-priming, we developed an in vitro system
where antigens (anti-Siglec-H-OVA) were only accessible to pDCs.
WT mice were treated with Flt3L for various days to expand the DC
populations, as previous studies have shown that both pDCs and
cDCs from Flt3L-treated mice exhibited similar expression profiles
as their counterparts in naive mice (74). Isolated pDCs were pulsed
with anti-Siglec-H-OVA plus CpG and washed thoroughly before

Downloaded at Henry Ford Health System on October 27, 2020

Fig. 3. Antigen-loaded pDCs required the help of
cDCs to prime antigen-specific CD8 T cell in vitro. (A
and B) While pDCs pulsed with anti-Siglec-H-OVA
plus CpG failed to prime naive OTI cells by themselves, these pDCs induced strong priming of naive
OTI cells in the presence of naive cDCs. pDCs were
pulsed with anti-Siglec-H-OVA plus CpG for 4 h and
cocultured with naive OTI cells (1 × 105 cells) either
with or without bystander splenic cDCs. Percentages
of proliferated CFSElow OTI are shown in A and the
percentages of proliferated IFN-γ+ cells (CFSElowIFNγ+) out of total OTI cells are shown in B. (C) pDCs
pulsed with anti-Siglec-H-OVA plus CpG transferred
antigens to antigen-naive cDCs. pDCs pulsed with
anti-Siglec-H-OVA plus CpG were cultured with
freshly isolated congenic cDCs (CD45.1 vs. CD45.2),
and subjected to flow cytometry. Expression of
MHCI-OVA on gated cDCs are shown. Data shown
are representative of three or more independent
experiments.

CD103+ cDC1s) play a critical role in cross-priming of antigenspecific CD8 T cells upon pDC-targeted vaccination.
We next asked whether the deficiency in OTI proliferation and
differentiation could be restored by increasing the number of
other cDCs to compensate for the lack of cDC1s. Batf3−/− mice
were treated with Flt3L for 8 to 9 d so that DCs other than
cDC1s were expanded. WT, naive Batf3−/− mice, and Flt3Ltreated Batf3−/− mice were then examined for cross-priming
upon immunization with anti-Siglec-H-OVA plus CpG. Flt3Ltreated Batf3−/− mice exhibited significantly increased percentages of both pDCs and cDCs (SI Appendix, Fig. S2A). The
proliferation of naive OTI CD8 T cells was partially restored in
Flt3L-treated Batf3−/− mice, with the percentage of OTI cells
that underwent six or more (more than five) rounds of proliferation increased to levels comparable to WT mice (SI Appendix,
Fig. S2 B and C). However, Flt3L treatment failed to restore
IFN-γ-producing effectors in Batf3−/− mice (Fig. 4 D and E, WT
vs. Flt3L-Batf3−/−), suggesting that increasing other DCs including pDCs and cDC2s, could not compensate for cDC1s’
function in priming naive CD8 T cells to differentiate into effector cells. However, it should be noted that Flt3L treatment
itself might lead to defective cross-priming through other
mechanisms. For instance, Flt3L-induced increased number/
level of pDCs has been shown to result in pDCs being more
tolerogenic to negatively regulate T cell functions (76). Similarly,
Flt3L treatment has been shown to expand regulatory T cells
(77), leading to suppressed CD8 T cell priming.
To directly determine whether cDC1s play a critical role in
pDC-mediated cross-priming, we turned to an in vitro coculture
system where only pDCs, cDCs, and CD8 T cells were present.
Proliferation and effector differentiation of OTI cells were greatly
reduced in cocultures with Batf3−/− splenic cDCs compared to WT
cDCs, with various numbers of cross-presenting pDCs (SI Appendix, Fig. S2D and Fig. 4F). The deficiency of Batf3−/− splenic cDCs
was not due to their inability in receiving OVA antigens from
pDCs, as both Batf3−/− splenic cDCs and WT CD8− cDC2s were
similar in their expression of MHCI-OVA on their surface upon
interaction with pulsed (cross-presenting) pDCs (SI Appendix,
Fig. S2E). Furthermore, similar percentages of MHCI-OVAexpressing cells were observed among WT CD8+ cDC1s and
CD8− cDC2s populations in WT cDCs (SI Appendix, Fig. S2 E, Upper),
23734 | www.pnas.org/cgi/doi/10.1073/pnas.2002345117

suggesting that CD8− cDC2s were equally efficient in acquiring antigens from pDCs compared to CD8+ cDC1s.
Taken together, our data suggest that while cross-presenting
pDCs transfer antigens to both cDC1s and cDC2s with similar
efficiency, cDC1s were intrinsically more potent in priming naive
CD8 T cells for effector differentiation compared to cDC2s and
play a critical role in pDC-targeted vaccination-induced crosspriming in vivo.
Antigen-Presenting pDCs Conditioned cDCs to Prime Antigen-Specific
CD8 T Cells by a Contact-Independent Mechanism. Next we asked

how pDCs transferred antigens to cDCs. Previous studies have
shown that through cell-cell contact, DCs could either acquire
preprocessed peptide (antigen) via gap junctions (78, 79), or the
preformed MHCI-antigen complexes from neighboring DCs or
other cells by “cross-dressing” (80–84). We thus asked whether
antigen transfer from pDCs to cDCs was also contact dependent.
We first examined whether supernatants of pulsed pDCs could
substitute pDCs to enable bystander cDCs to prime OTI cells.
Isolated pDCs were pulsed with anti-Siglec-H-OVA plus CpG
and were extensively washed before plating. Addition of pDC
supernatants to cDC/OTI cocultures led to a dose-dependent
increase in proliferation, whereas addition of pDC supernatants to OTI cells induced no proliferation (Fig. 5A). Further
examination also confirmed that significant percentages of the
proliferating OTI cells differentiated into IFN-γ-producing effectors (Fig. 5A), suggesting that pDC-produced soluble factor(s)
could confer on cDCs the ability to prime naive CD8 T cells.
Transwell experiments also confirmed that pDC-derived soluble
factor(s) is responsible for inducing cDC-dependent CD8 T cell
priming. cDCs/OTI cocultures were placed in 3 μM Transwell,
and pDCs pulsed with anti-Siglec-H-OVA plus CpG were cultured in the outer chamber. Indeed, we observed significant
proliferation of OTI cells in Transwell if large numbers of pulsed
pDCs were placed in the outer chamber (SI Appendix, Fig. S3A),
further confirming that antigen-presenting pDCs induced cDCs
to prime CD8 T cells in a contact-independent manner.
As our data have suggested pDCs transferred antigens to
cDCs to prime CD8 T cells, we asked whether pDC supernatants
also transferred antigens to cDCs. Coculture of naive cDCs with
pDC supernatants led to significant expression of MHCI-OVA
Fu et al.

IMMUNOLOGY AND
INFLAMMATION

Fig. 4. Batf3-depedent cDC1s played a critical role in pDC-mediated cross-priming in vivo. (A–C) Batf3−/− mice exhibited significantly reduced cross-priming.
WT and Batf3−/− mice (n = 5) were examined for cross-priming as in Fig. 1. The percentages of Thy1.1+ OTI cells out of total CD8 T cells were depicted with
representative plots in A, Upper; the percentages of Thy1.1+ OTI cells that had undergone more than five cycles of proliferation are depicted in B; and the
percentages of IFN-γ+ cells out of total Thy1.1+ OTI cells are depicted in C. (D and E) Increasing the number of DCs in Batf3−/− mice failed to restore crosspriming. WT, Batf3−/−, and Flt3L-treated Batf3−/− mice (n = 4) were examined for cross-priming as in C. The percentages of IFN-γ+ cells out of total Thy1.1+ OTI
cells are shown for both spleen and LNs in D with representative plots and in E with bar graph for statistics analysis. (F) WT but not Batf3−/− cDCs were able to
mediate efficient priming of OTI cells by WT pDCs in vitro. WT pDCs pulsed with anti-Siglec-H-OVA plus CpG were cocultured with naive OTI cells (1 × 105 cells)
and 2 × 104 WT or Batf3−/− cDCs as indicated. Percentages of proliferated IFN-γ+ cells (CFSElowIFN-γ+) out of total OTI cells are shown. Data are representative
of two or more independent experiments. NS = P > 0.05%, *P < 0.05, **P < 0.01, and ***P < 0.001.
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(H-2Kb-SIINFEKL) on cDCs (SI Appendix, Fig. S3B). Taken
together, our data suggest that pDCs confer on bystander cDCs the
ability to prime CD8 T cells in a cell contact-independent manner,
likely by transferring antigens to cDCs through soluble factor(s).
pDC-Generated Exosomes Transferred Antigens to Naive cDCs,
Rendering These cDCs Competent for Priming of Antigen-Specific CD8
T Cells. Next we investigated what soluble factors were employed by

pDCs to transfer antigens to cDCs. As DCexos have been shown
to transfer MHC/antigen complexes by cross-dressing (85–87), and
Fu et al.

the size of exosomes (30 to 150 nM in diameter) would allow them
easy passage through the 3-μM pores of the Transwells we used in
SI Appendix, Fig. S3A, we thus asked whether pDCs generated
exosomes and if so, whether pDCexos mediated antigen transfer
from pDCs to cDCs. pDCs were cultured in media containing
exosome-free fetal bovine serum (FBS) with anti-Siglec-H-OVA
plus CpG, and exosomes were purified according to the manufacturer’s manual. Western blot analysis showed that pDCexos
were positive for exosome markers CD63, TSG101 (Fig. 5B),
confirming that pDCs cultured with anti-Siglec-H-OVA plus CpG
PNAS | September 22, 2020 | vol. 117 | no. 38 | 23735
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Fig. 5. Antigen-presenting pDCs conditioned cDCs to prime
antigen-specific CD8 T cells by a contact-independent mechanism, likely through pDC-derived exosomes. (A) pDC-produced
supernatants induced a dose-dependent priming of naive OTI
cells that was dependent on the presence of cDCs. pDCs were
pulsed with anti-Siglec-H-OVA plus CpG and thoroughly
washed before culture. Culture supernatants were added to
OTI cells in the presence or absence of naive cDCs as indicated.
Percentages of total proliferated cells (CFSElow) and proliferated IFN-γ+ cells (CFSElowIFN-γ+) out of total OTI cells are
shown. (B) pDCs-generated exosomes were enriched for exosome markers CD63 and Tsg101. pDCs were cultured with
anti-Siglec-H-OVA and CpG, and exosomes were isolated using
an Invitrogen kit. Isolated exosomes and total cell lysates were
subjected to Western blot for CD63, Tsg101, and β-actin. (C)
pDCs-produced exosomes transferred antigens to cDCs. cDCs
were cultured either alone or with pDCs-generated exosomes
and subjected to flow cytometry. Expression of MHCI-OVA (H2Kb-SIINFEKL) on cDCs is shown. (D) pDCs-produced exosomes
induced a dose-dependent priming of naive OTI cells that is
dependent on the presence of cDCs. pDCs-generated exosomes were added to OTI cells in the presence or absence of
naive cDCs and subjected to flow cytometry. Percentages of
total proliferated cells (CFSElow) and proliferated IFN-γ+ cells
(CFSElowIFN-γ+) out of total OTI cells are shown. Data shown
are representative of three or more independent experiments.

indeed generated exosomes. Nanoparticle tracking analysis (NTA)
of the isolated exosomes revealed homogenous size distributions
with median diameter of 83 ± 1.3 nM and about 1.4 ± 0.2 × 109
exosomes/106 pDCs in one representative preparation.
Next we asked whether pDCexos transferred antigens to
cDCs. pDCexos were cultured with freshly isolated cDCs, and
the expression of MHCI-OVA (H-2Kb-SIINFEKL) was examined. As shown in Fig. 5C, addition of pDCexos (at 200 μL/1 ×
106 pDCs) led to significant up-regulation of MHCI-OVA in
bystander cDCs, suggesting that pDCexos indeed transferred
OVA antigen to cDCs. We thus asked whether pDCexos could
similarly render naive bystander cDCs competent for CD8 T cell
priming. Addition of pDCexos to cDC/OTI cocultures led to a
dose-dependent increase in OTI proliferation and their differentiation into IFN-γ-producing effectors, whereas addition of
pDCexos to OTI cells without bystander cDCs induced no proliferation (Fig. 5D). Thus, our data suggest that pDCs targeted by
anti-Siglec-H-OVA employ a mechanism to prime antigen-specific
CD8 T cells by transferring antigens to cDCs through exosomes.
In addition to TLR9, pDCs also express TLR7, and stimulation with TLR7 agonist R848 and CpG (1668, type B) have been
shown to lead to distinctively different activation-induced pDC
populations (5). We thus asked whether targeting pDCs with
anti-Siglec-H-OVA plus the TLR7 agonist R848 cross-prime
naive CD8 T cells through exosomes. Exosomes were isolated
from supernatants of pDCs cultured with anti-Siglec-H-OVA
plus R848. Similar to exosomes generated from pDCs cultured
with anti-Siglec-H-OVA plus CpG, R848-treated pDC-derived
exosomes induced OTI proliferation and their differentiation
into IFN-γ-producing effectors only in the presence of bystander
cDCs (SI Appendix, Fig. S4A). Thus, pDC-targeted vaccine via
Siglec-H with either TLR7 or TLR9 agonists as adjuvant crossprimed naive CD8 T cells through a similar mechanism involving
exosomes.
As we had clearly shown that cross-presenting pDCs achieved
cross-priming through pDCexos with model antigen ovalbumin,
we next asked whether pDCexo-mediated cross-priming also
applied to other antigens. We have thus cloned the human
melanoma antigen gp100 (hgp100) into anti-Siglec-H-OVA
constructs to express anti-Siglec-H-hgp100. Exosomes were
similarly isolated from pDCs cultured with anti-Siglec-H-hgp100
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plus CpG, and added to gp100-specific CD8 T cells (pme-1) with
or without cDCs. While addition of pDCexos to cDCs/pmel-1 led
to significant pmel-1 cell proliferation and differentiation into
IFN-γ-producing effectors, addition of pDCexos to pmel-1 cells
without bystander cDCs led to no proliferation (SI Appendix, Fig.
S4B), suggesting that the mechanism of pDCexo-mediated cDCdependent cross-priming is not limited to OVA antigen.
Taken together, our data suggest that pDCs targeted by antiSiglec-H-antigens employ a mechanism to prime antigen-specific
CD8 T cells by transferring antigens to cDCs through exosomes.
pDCs Treated with Anti-Bst2-OVA or Soluble OVA Protein Similarly
Produced Exosomes to Cross-Prime OVA-Specific CD8 T Cells by
Transferring Antigens to cDCs. As Siglec-H exhibits distinct func-

tions in pDCs (48, 88), we asked whether the mechanism that
pDCs enable cDCs to prime CD8 T cells by transferring antigens
to cDCs through exosomes is unique to targeting pDCs via
Siglec-H. We had previously generated another pDC-targeting
antibody against pDC receptor Bst2 (72), which differs from
pDC-targeted anti-Siglec-H-antigen in inducing CD4 and CD8
T cell immunity (71).
We first asked whether targeting pDCs with anti-Bst2-OVA
also required cDCs to cross-prime antigen-specific CD8 T cells.
CD11c-DTR→WT bone marrow chimeras were treated with DT
and cross-priming was examined as with anti-Siglec-H-OVA.
While chimeras treated with PBS exhibited strong cross-priming
of naive OTI cells resulting in strong proliferation and differentiation into IFN-γ-producing effectors following immunization
of anti-Bst2-OVA plus CpG, both OTI cell proliferation and
differentiation into IFN-γ-producing effectors were significantly
impaired in DT-treated chimeras (Fig. 6 A and B), suggesting
that cDCs are also required for cross-priming by in vivo DC
vaccine targeting pDCs with anti-Bst2-OVA.
We next asked whether pDCs targeted by anti-Bst2-OVA
employed a similar mechanism involving exosomes to cross-prime
OTI CD8 T cells. Addition of exosomes from pDCs cultured with
anti-Bst2-OVA plus CpG to naive cDCs led to the expression of
MHCI-OVA (H-2Kb-SIINFEKL) on these cDCs (Fig. 6C), suggesting that exosomes from pDCs targeted by anti-Bst2-OVA
similarly mediated the transfer of antigens to cDCs. More importantly, exosomes from pDCs cultured with anti-Bst2-OVA plus
Fu et al.
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Fig. 6. pDCs treated with anti-Bst2-OVA and soluble ovalbumin protein similarly generated exosomes to cross-prime OVA-specific CD8 T cells by transferring
antigens to cDCs. (A and B) cDCs play a critical role in cross-priming upon immunization with pDC-targeting anti-Bst2-OVA and CpG. CD11c-DTR→WT bone
marrow chimeras (n = 4) were treated with DT or PBS on days −2, 0, and 2, and immunized with anti-Bst2-OVA plus CpG following adoptive transfer of CFSElabeled naive OTI cells. The percentages of Thy1.1+ OTI cells out of total CD8 T cells are depicted in A, and the percentages of IFN-γ+ cells out of total Thy1.1+
OTI cells are shown in B. (C) cDCs expressed functional MHCI-OVA upon coculture with pDC-derived exosomes. cDCs were cultured alone or with exosomes
from pDCs treated with anti-Bst2-OVA plus CpG, and subjected to flow cytometry. Expression of MHCI-OVA (H-2Kb-SIINFEKL) on cDCs is shown. (D) Exosomes
from WT pDCs treated with anti-Bst2-OVA plus CpG induced cDC-dependent priming of naive OTI CD8 T cells. WT pDCs were cultured with anti-Bst2-OVA plus
CpG and isolated exosomes were added to OTI cells in the presence or absence of naive WT cDCs. Percentages of total proliferated cells (CFSElow) and
proliferated IFN-γ+ cells (CFSElowIFN-γ+) out of total OTI cells were shown. (E) Exosomes from WT pDCs treated with OVA protein plus CpG induced cDCdependent priming of naive OTI CD8 T cells. WT pDCs were cultured with soluble OVA protein plus CpG, and isolated exosomes were cultured with naive OTI
cells with or without bystander cDCs. OTI cell proliferation and differentiation are presented as in D. (F) cDCs expressed functional MHCI-OVA upon coculture
with exosomes from pDCs treated with ovalbumin protein. cDCs were cultured alone or with exosomes from pDCs treated with soluble OVA protein and
subjected to flow cytometry. Expression of MHCI-OVA (H-2Kb-SIINFEKL) on cDCs is shown. Data shown are representative of at least two independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001.

CpG similarly induced a dose-dependent proliferation and effector
differentiation of naive OTI cells in the presence of cDCs (Fig. 6D),
suggesting that pDCs targeted with anti-Bst2-antigen (OVA) and
anti-Siglec-H-antigen shared the mechanism of transferring antigens
via exosomes to cDCs to cross-prime antigen-specific CD8 T cells.
As activated pDCs have been shown to cross-present soluble
protein in vivo (46), we asked whether pDCs might produce
exosomes for cross-priming with soluble proteins. Not surprisingly,
Fu et al.

exosomes from pDCs cultured with soluble OVA protein primed
naive OTI cells only in the presence of cDCs (Fig. 6E), suggesting
that pDCs loaded with soluble proteins might also prime antigenspecific CD8 T cells through a cDC-dependent mechanism mediated by pDCexos. Addition of exosomes from pDCs cultured
with OVA protein plus CpG to naive cDCs led to the expression
of MHCI-OVA on these cDCs (Fig. 6F), suggesting that exosomes
from pDCs loaded with soluble OVA protein could similarly
PNAS | September 22, 2020 | vol. 117 | no. 38 | 23737
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mediate the transfer of antigens to cDCs. Taken together, our
studies suggested that pDCs could employ an exosome-mediated
and cDC-dependent mechanism for cross-priming under multiple
settings.
Discussion
In this report we have identified a cDC-dependent mechanism
for pDCs to achieve cross-priming in vivo. Although extensive
studies have shown that pDCs play critical roles in viral immunity, autoimmunity, and immune tolerance, conflicting results on
whether pDCs played a critical role in cross-priming in vivo have
been reported (41, 43, 45–48). Surprisingly, the opposite results
seem to be on the priming of CD8 T cells instead of crosspresentation, as both human and murine pDCs have been
shown to be capable of cross-presentation (33–37, 46). The involvement of pDCs in cross-presentation in vivo is further supported by recent evidence suggesting that pDCs transported
antigens to promote immune tolerance in vivo (74, 89). However, the efforts to delineate the precise role of pDCs in crosspriming in vivo were further complicated as IFN-I produced by
pDCs efficiently activates and recruits cDCs, B cells, T cells, and
NK cells to indirectly affect CD8 T cell priming (90). In this
report, we were able to delineate the contribution of pDCs
versus cDCs in in vivo cross-priming and uncover an unexpected
mechanism by which cross-presenting pDCs required cDCs to
cross-prime CD8 T cells in vivo, taking advantage of a pDCtargeted vaccine model which confines cross-presentation specifically to pDCs. Using an in vitro culture system where we only
allowed pDCs the access to antigens, we further demonstrated
that cross-presenting pDCs primed naive antigen-specific CD8
T cells only in the presence of bystander cDCs, thus confirming
the requirement of cDCs for pDCs to achieve cross-priming.
Moreover, the in vitro system allowed us to directly demonstrate
that cross-presenting pDCs transferred antigens to bystander
cDCs, consistent with our observation in vivo. Taken together,
this report uncovers a mechanism that cross-presenting pDCs
achieve cross-priming by transferring antigens to cDCs in vitro
and in vivo. This mechanism that cross-presenting pDCs require
the help of cDCs to prime CD8 T cells by transferring antigens to
bystander cDCs has not been previously reported, and likely
provides a mechanistic explanation for the reported opposite
results regarding whether pDCs cross-prime CD8 T cells in vivo.
For instance, the lack of cross-priming by pDCs in cDC-depleted
CD11c-DTR mice (45), similar to our observation (Fig. 1), could
be explained by the requirement of cDCs instead of pDCs’ inability to cross-prime CD8 T cells in vivo. Our findings additionally provide a mechanism for the synergistic effects of pDCs
and cDCs on cross-priming. Of note, recent studies have shown
that both pDCs and cDCs are required to achieve optimal crosspriming and CD8 T cell immunity under diverse conditions
(50–55), although the underlying mechanisms for the synergy
were not well understood. In light of our findings, future studies
are warranted to determine whether and how pDC-mediated
antigen transfer to cDCs plays a role in enhancing crosspriming and CD8 T cell immunity.
Another interesting finding was that while CD4 T cell tolerance
was observed upon immunization with anti-Siglec-H-OVA without
or with adjuvants (71), CD8 T cell tolerance was only observed
upon immunization with anti-Siglec-H-OVA alone. Addition of the
TLR9 agonist CpG, which directly activated both pDCs and cDCs,
reversed CD8 T cell tolerance leading to CD8 T cell immunity,
suggesting that immunization with anti-Siglec-H-OVA plus adjuvants simultaneously led to CD4 T cell tolerance and CD8 T cell
immunity. The observed CD8 T cell immunity is not entirely surprising, as immunization with OVA-conjugated anti-Siglec-H plus
CpG has previously been shown to generate CD8 T cell immunity,
presumably through cross-presentation (91). Furthermore, pDCs
have been shown to play a negative role in CD4 T cell responses
23738 | www.pnas.org/cgi/doi/10.1073/pnas.2002345117

but a positive role in CD8 T cell immunity in vivo (48). How pDCs
achieved CD8 T cell immunity while maintained CD4 T cell tolerance is not entirely clear. However, neither regulatory T cells nor
the maturation/cytokine production of pDCs (by comparing pDCs
upon immunization of anti-Siglec-H-OVA and anti-Bst2-OVA
plus CpG) has been shown to play a role in CD4 T cell tolerance
(71), suggesting that CD4 and CD8 T cell tolerance might be independent instead of systematically regulated. Interestingly, while
MHCI-Ag complexes were detected in both pDCs and cDCs,
MHCII-Ag complexes were only observed on pDCs but not cDCs
(71), suggesting that cDCs were used differently in the priming of
CD4 versus CD8 T cells. Further studies are required to elucidate
the mechanisms of how pDC-targeted immunization through
Siglec-H differentially regulates CD4 and CD8 T cell tolerance/
responses.
Among cDCs, Batf3-dependent cDC1s are recognized as the
superior APCs in cross-presenting exogenous antigens including
tumor antigens to prime CD8 T cells (75, 92, 93). However,
cDC2s have also been shown to play a preeminent role in
priming CD8 T cells in studies of cross-dressed DCs. For instance, although both cDC1s and cDC2s have been shown to
prime CD8 T cells by acquiring antigens through cross-dressing
(81), cross-dressed CD8− cDC2s but not CD8+ cDC1s have been
shown to play a critical role in CD8 T cell priming in viral infection models (82, 84). As to whether cDC2s were the preferred
recipients of antigens was not directly examined, it remains to be
determined whether the critical role of cDC2s was due to their
enhanced abilities at acquiring antigens and/or priming CD8
T cells. On the other hand, Li et al. have shown that crossdressed Batf3-dependent cDC1s played a critical role in priming both naive and memory CD8 T cells after DNA and cellular
vaccination (83). However, a direct comparison of cDC1s and
cDC2s in acquiring antigens was not performed in this study,
thus it’s also unclear whether cDC1s’ critical role was due to
their capacity in acquiring antigens or priming CD8 T cells. In
this report, we were able to show that Batf3-dependent cDC1s
have a nonredundant role in priming naive CD8 T cells to differentiate into effector cells. Furthermore, we have also demonstrated that CD8− cDC2s and CD8+ cDC1s were equally
efficient in acquiring antigens from pDCs, indicating that cDC1s’
essential role in cross-priming CD8 T cells for effector differentiation is independent of their ability in cross-presentation or
receiving antigens from pDCs. Thus, while this study has focused
on the expression of MHCI-Ag complexes or Signal 1 on bystander cDCs through antigen transfer, other mechanisms, including maturation (Signal 2), cytokine production such as IL-12
(Signal 3) of cDC1s, and pDC/pDCexo-mediated transfer of
other molecules besides antigens, likely contribute to the critical
roles cDC1s play in pDC-mediated cross-priming. Indeed, IL-12
production by cDC1s has been shown to play a critical role in
cross-priming and CTL responses in a tumor setting (94), although the involvement of cDC1-produced IL-12 in CD8 T cell
priming might be context dependent (95, 96). Taken together,
our data suggest that cDC1s also exhibit increased capacity in
priming CD8 T cells to differentiate into effectors compared to
cDC2s postantigen presentation. It’s interesting to note that in Li
et al.’s and our studies on vaccination models, cDC1s played a
critical role in cross-priming after acquiring antigens (83), while
cDC2s were the critical player in viral infection (82, 84), suggesting that cDC1s and cDC2s might have a division of labor in
cross-priming depending on different settings. Together, these
studies depict a picture that different coordination/cooperation
of multiple subsets of DCs are utilized to mount sophisticated
immune responses to diverse challenges. Thus, it will be interesting to investigate the roles and regulation of cDC1s and
cDC2s in cross-priming with regards to their acquiring antigens
and priming CD8 T cells under different conditions, including
viral infection, inflammation, and vaccination.
Fu et al.
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Materials and Methods
Mice. C57BL/6, CD11c-DTR, Batf3−/−, and the gp100-specific TCR transgenic
Thy1.1+ Pmel-1 mice were purchased from The Jackson Laboratory. CD45.1
mice were purchased from Charles River Laboratories. CD8 TCR transgenic
Thy1.1+ Rag1−/− OTI mice were generated as described previously (105), and
Thy1.1+ Rag1−/− Pmel-1 mice were generated similarly. For the generation of
bone marrow chimeras, lethally irradiated CD45.1 B6 mice were reconstituted with 3 to 5 × 106 bone marrow cells containing CD11-c-DTR bone
marrow cells (CD45.2). All procedures on animals followed protocols approved by the Institutional Animal Care and Use Committee at Roswell Park
Comprehensive Cancer Center.
Antibodies and Reagents. Anti-CD11c and anti-mPDCA-1 (Bst2) magnetic
microbeads, antibodies to Siglec-H, Bst2, and B220, mouse CD8α+ T cell isolation kit, mouse plasmacytoid DC isolation kit, and mouse pan DC isolation
kit were purchased from Miltenyi Biotec. Anti-Siglec-H-OVA and anti-Bst2OVA have been described previously (71, 72). Recombinant human Flt3-L
was purchased from BioXcell. Antibodies to Thy1.1, TCR Vα2, and Vβ5.1/5.2,
Vβ13, CD8α, Siglec-H, Bst-2, B220, CD63, CD45.1, CD45.2, CD44, CD62L, CD80,
CD86, MHC class II I-Ab, and TNF-α were purchased from Biolegend Inc.
Brefeldin A (BFA), antibodies to CD11c, H-2Kb-SIINFEKL, and IFN-γ were
purchased from eBioscience. Total exosome isolation kits (from cell culture
media) were purchased from Thermo Fisher Scientific. CpG 1668 was purchased from Invitrogen or obtained from Oligo Factory. The 3-μM cell Falcon
culture inserts were purchased from Corning. Staining for surface and intracellular antigen expression was performed as previously described (106).
In brief, cells from spleen and pooled draining LNs were stimulated for 5 h
with OTI or hgp10025–33 peptide (1 to 4 μg/mL, AnaSpec Inc.) in the presence
of BFA (5 μg/mL), stained for cell surface protein expression followed by
fixation and permeabilization, and staining for intracellular antigens like
IFN-γ. Where indicated, OTI CD8 T cells were labeled with CFSE and checked
by flow cytometry before transfer. We used a Fortessa (BD Biosciences) with
subsequent data analysis using FlowJo (Tree Star).
Isolation and Purification of TCR Transgenic CD8 T Cells and DCs. Naive OTI and
Pmel-1 Thy1.1+ CD8 T cells were isolated from pooled LNs of Thy1.1+ Rag1−/−
OTI and Thy1.1+ Rag1−/− Pmel-1 mice, respectively, and routinely checked
with Thy1.1, CD44, and CD62L for purity and activation. The percentages of
Thy1.1+ cells were around 85 to 95%. For cross-priming assays, either in vivo
or in vitro, naive OTI Thy1.1+ CD8 T cells were labeled with 5 μM CFSE
(Molecular Probes) in 5% FCS PBS at room temperature for 15 min and
washed three times before injection or plating. To expand DCs, mice were
injected with Flt3-L for 6 to 15 d. To purify total DCs from spleen, we used
either anti-CD11c-conjugated beads or pan-DC isolation kit and columns
(Miltenyi Biotech) following the manufacturer’s protocols. For isolation of
cDCs depleted of pDCs, we have modified the protocol to use anti-Siglec-Hbiotin, anti-B220-biotin, and either anti-Bst2-biotin or anti-Bst2 microbeads
together with pan-DC isolation kit. The isolated cDCs generally contain <2%
of pDCs. To purify pDCs, mice were generally treated with Flt3-L for 12 to
15 d when the percentages of cDCs start to turn lower. Flt3L-treated mouse
spleen cells were first incubated with small amounts of anti-CD11c
microbeads to deplete cDCs, followed by pDC isolation with anti-Bst2
microbeads according to the manufacturer’s protocols. The isolated pDCs
generally contain <5% of CD11chigh cDCs.
Immunization and DT Treatment. For immunization (vaccination), antiSiglec-H-OVA and anti-Bst2-OVA (10 to 20 μg/per mouse) were injected i.v.
into the tail veins in 200 μL PBS, and CpG (50 to 100 μg/per mouse) was injected s.c. at two sites on hind legs in 200 μL PBS. For studying DC
vaccination-induced CD8+ T cell responses, 0.5 to 2 × 106 naive OTI Thy1.1+
CD8+ T cells were adoptively transferred i.v. into tail veins 1 d before immunization. Mice were examined 3 to 4 d after immunization for primary
CD8 T cell response: briefly, LN and spleen cells were stimulated for 5 h in the
presence of BFA and OTI peptide, stained for surface Thy1.1, CD8, and intracellular cytokines (i.e., IFN-γ), and evaluated by flow cytometry. For
recalled CD8 T cell response, immunized mice were challenged at day 21
after immunization, with chicken ovalbumin (Worthington Biochemical) and
CFA (Sigma-Aldrich) emulsion that was injected s.c. into four legs in 200 μL,
and spleen and LN cells were examined for CD8 T cells response as above 5 d
after challenge. For DT experiments with CD11c-DTR→WT bone marrow
chimeras, chimeric mice were treated with DT or PBS on days −2, 0, and 2,
and immunized on day 0.
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As pDCexos have not been reported, current studies of
DCexos are almost exclusively focusing on exosomes from cDCs
(65, 97). These DCexos (exosomes from cDCs) have been shown
to prime CD8 T cells either directly, or indirectly by transferring
antigens to bystander DCs (82, 86, 87, 98), thus providing an
alternative mechanism for cDCs to achieve cross-priming. Using
a pDC-targeted vaccine model, we have now demonstrated that
pDCs produced exosomes, and these pDCexos mediated antigen
transfer from pDCs to bystander cDCs. Functionally, pDCexos
primed naive antigen-specific CD8 T cells only in the presence of
bystander cDCs, similarly to cross-presenting pDCs. Together
with our finding that cross-presenting pDCs were unable to efficiently prime naive antigen-specific CD8 T cells by themselves,
our data suggested that pDCs employed a unique mechanism of
pDCexo-mediated antigen transfer to cDCs to achieve crosspriming. The generation of pDCexos was not limited to the
model system we used, which targeted model antigen ovalbumin
to Siglec-H on pDCs. We have additionally shown that pDCexos
were generated by pDCs under various conditions including with
a tumor antigen, with antigen targeted to Bst2 and soluble protein. More importantly, all these pDCexos similarly primed
antigen-specific CD8 T cells only in the presence of bystander
cDCs, suggesting that the pDCexo/cDCs pathway might also play
a role in cross-priming under these settings. However, whether
the pDCexo/cDCs pathway plays a critical role in cross-priming
when soluble proteins not specifically targeted to pDCs were
administrated in vivo is not clear. In this regard, previous studies
on pDCs’ function in cross-priming CD8 T cells upon administration of soluble OVA might provide some insight. Using
Siglec-H-DTR mice, Takagi et al. have shown that OVA-specific
CD8 T cell responses were reduced after pDC depletion, suggesting that pDCs might play a positive role in cross-priming
CD8 T cells (48). However, other Siglec-H+ cells such as macrophages instead of pDCs might also be responsible for the reduced cross-priming, and whether pDCs functioned in crosspriming with OVA antigens and whether cDCs were required
for pDCs’ function in cross-priming were not directly examined
(48). In another study by Mouriès et al., isolated pDCs from mice
that were administrated soluble OVA have been shown to prime
naive OTI cells ex vivo (46), suggesting that cDCs and the
pDCexo/cDCs pathway were not required or involved for pDCs’
function in cross-priming. Thus, whether antigens were specifically targeted through receptors to pDCs or not likely affects
whether pDCs cross-present such antigens and employ the
pDCexo/cDCs pathway to cross-prime CD8 T cells in vivo. In
light of our findings on pDCexos, future work is warranted to
directly test whether pDCs transfer different nontargeted antigens through pDCexos to promote cross-priming in vivo. DCexos
have garnered much interest for their potential as cell-free
therapeutic agents, as being inert vesicles they are more resistant to immunomodulation (i.e., tumor microenvironment) and
amenable to the manufacturing process at lower cost compared
to DCs (65, 99). Indeed, vaccines with tumor antigen-pulsed
DCexos have exhibited better efficacy than DC vaccines in preclinical tumor models (100). In a transplantation model, a recent
study has shown that donor DCexos (from cDCs) instead of DCs
also played a major role in priming allogenic CD4 and CD8
(cross-priming) T cells (101). However, all three DCexo clinical
trials using autologous antigen-loaded DCexos (from cDCs)
failed to generate the desired T cell responses (102–104), suggesting that there’s a critical need to better understand how
DCexos mediate cross-priming. The identification of pDCexos
and their function in cross-priming thus offered a welcome addition to the DCexo repertoire. Further studies of these identified pDCexos are required to determine their function/
regulation and potential application.
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Cross-Priming Assays and DC-T Cell Cocultures. For in vivo cross-priming assay,
mice were immunized with anti-Siglec-H-OVA, or anti-Bst2-OVA plus CpG,
followed by adoptive transfer of 0.5 to 2 × 106 CFSE-labeled naive Thy1.1+
OTI cells. LN and spleen cells were isolated 3 to 4 d after immunization,
stimulated for 5 h in the presence of BFA and OTI peptide, stained for surface Thy1.1, CD8, and intracellular antigens like IFN-γ, and subjected to flow
cytometry to evaluate proliferation by CFSE dilution and effector differentiation by IFN-γ production. For cross-priming of Flt3-L-treated Batf3−/− mice,
Batf3−/− mice were treated with Flt3-L every day for the duration of the
experiments, immunized with anti-Siglec-H-OVA plus CpG on day 9 following OTI adoptive transfer.
For in vitro cross-priming, 1 × 105 naive OTI cells were cultured in
u-bottom 96-well plates, and 2 × 104 cDCs were added when indicated. For
pulsed pDCs, isolated pDCs were pulsed with anti-Siglec-H-OVA, or anti-Bst2OVA plus CpG for 4 h, thoroughly washed and added to OTI as indicated. For
pDC supernatants, pulsed pDCs were cultured for 2 to 3 d and supernatants
were obtained by centrifugation. For pDC-derived exosomes, exosomes from
1 × 106 pDCs (about 1.4 ± 0.2 × 109 exosomes) were resuspended in 200 μL of
cultured media and added to OTI with or without cDCs as indicated. The
various cocultures were stimulated for 5 h in the presence of BFA and antigens and subjected to flow cytometry to evaluate proliferation by CFSE
dilution and effector differentiation by IFN-γ production.

Isolation and Analysis of Exosomes. pDCs were cultured in RPMI media with
exosome-depleted FBS, and exosomes were obtained by using Total Exosome Isolation Kit according to the manufacturer’s protocols. NTA of the
isolated exosomes was carried out with Zetaview (Particle Metrix, Gmbh).
For Western blotting, pDC-produced exosomes were lysed and subjected to
Western blot analysis with anti-β-actin, anti-CD63, and anti-Tsg101 according to the manufacturer’s protocols.
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